Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM79DSN)

• Drug Name: ABTAA Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Sepsis	1G40-1G41	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DM79DSN

Molecule-Related Drug Atlas

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[2]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[3]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[4]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[5]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[6]
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[7]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[8]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[10]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Drug(s) Targeting Angiopoietin 1 receptor (TEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKB-9778	DMKNRYH	Diabetic macular edema	9B71.02	Phase 2	[12]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[7]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
ARRY-614	DMXD93K	Arthritis	FA20	Discontinued in Phase 1	[15]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[16]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[16]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[16]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[16]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin 1 receptor (TEK)	TT9VGXW	TIE2_HUMAN	Activator	[1]
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Binder	[1]

References

• [1] Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.
• [2] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [5] Company report (Roche pipeline: July 27, 2017)
• [6] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [9] Clinical pipeline report, company report or official report of CovX (2011).
• [10] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [11] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
• [15] Cmpany report (Arraybiopharma)
• [16] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [17] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.